Sanofi won approval for the use of a drug combination with its Sarclisa infusion to treat certain types of newly diagnosed ...

Sanofi and Regeneron’s blockbuster drug Dupixent successfully treated patients with chronic spontaneous urticaria, an inflammatory skin disease, in a late-stage trial, the companies announced on ...

MC: There is no old or new model, but there is old school thinking and open school thinking. We are clearly conscious of this within Sanofi and we truly believe that we will overcome the future ...

Sanofi said an oral treatment for multiple sclerosis, tolebrutinib, met its key goal in a Phase 3 study, potentially clearing the way for regulatory approval, although in two other studies ...

Although the latest news from the laboratory was mixed for pharmaceutical company Sanofi (NASDAQ: SNY) on Tuesday, investors gave the company the benefit of the doubt. They bid the share price up ...

Sept 2 (Reuters) - Sanofi's (SASY.PA), opens new tab most advanced multiple sclerosis drug candidate has missed the main goal of two late-stage trials to treat relapsing forms of the disease ...

Sanofi has made a late entry to the radioligand party, paying 100 million euros ($110 million) upfront for global rights to a neuroendocrine tumor treatment that is nearing a filing for approval.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Company planning for every eligible baby in the US to have access to BEYFORTUS New BEYFORTUS filling ... disease1 BRIDGEWATER, N.J., Sept. 16, 2024 /PRNewswire/ -- Sanofi is shipping BEYFORTUS ...

In 2022, concerns over liver damage led to a halt in the enrolment of new patients in three of Sanofi's tolebrutinib studies that were still recruiting volunteers at the time. On Monday ...